Evidence map›Paper›PMID 30458305›Full record

ArticleNeuroImage2019

Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Michael J Properzi, Rachel F Buckley, Jasmeer P Chhatwal, Michael C Donohue, Cristina Lois, Elizabeth C Mormino, Keith A Johnson, Reisa A Sperling, Aaron P Schultz

Abstract read
In one paragraph

Article in NeuroImage, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  16. Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Operationalizing the centiloid scale for [Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael J ProperziHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Rachel F BuckleyHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; The Florey Institute, The University of Melbourne, Victoria, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Victoria, Australia.
Jasmeer P ChhatwalHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Michael C DonohueAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.
Cristina LoisDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Elizabeth C MorminoDepartment of Neurology, Stanford University, CA, USA.
Keith A JohnsonHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Reisa A SperlingHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Aaron P SchultzHarvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. Electronic address: aschultz@nmr.mgh.harvard.edu.

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI FROSCH, MATTHEW P · 1985 to 2018
$42.1M
Project 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8M
Evolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6M
Vascular Dysfunction in Cerebral Amyloid AngiopathyR01AG026484 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2005 to 2019
$7.5M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MARCUS, DANIEL SCOTT · 2008 to 2009
$6.1M
Characterizing the Evolution of Amyloid Deposition in Normal ElderlyR01AG037497 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2010 to 2014
$3.2M
NCRR NIH HHS S10 RR021110NCRR NIH HHS S10 RR023043NCRR NIH HHS S10 RR023401NIA NIH HHS K23 AG049087NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG036694NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG026484NIA NIH HHS R01 AG027435NIA NIH HHS R01 AG034556NIA NIH HHS R01 AG037497NIA NIH HHS R21 AG038994NIA NIH HHS R21 AG060221NIA NIH HHS U01 AG010483NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIBIB NIH HHS P41 EB015896NIBIB NIH HHS R01 EB014894
6 · The paper itself

Abstract

introductionThere is a growing need in clinical research domains for direct comparability between amyloid-beta (Aβ) Positron Emission Tomography (PET) measures obtained via different radiotracers and processing methodologies. Previous efforts to provide a common measurement scale fail to account for non-linearities between measurement scales that can arise from these differences. We introduce a new application of distribution mapping, based on well established statistical orthodoxy, that we call Nonlinear Distribution Mapping (NoDiM). NoDiM uses cumulative distribution functions to derive mappings between Aβ-PET measurements from different tracers and processing streams that align data based on their location in their respective distributions.

methodsUtilizing large datasets of Florbetapir (FBP) from the Alzheimer's Disease Neuroimaging Initiative (n = 349 female (%) = 53) and Pittsburgh Compound B (PiB) from the Harvard Aging Brain Study (n = 305 female (%) = 59.3) and the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (n = 184 female (%) = 53.3), we fit explicit mathematical models of a mixture of two normal distributions, with parameter estimates from Gaussian Mixture Models, to each tracer's empirical data. We demonstrate the accuracy of these fits, and then show the ability of NoDiM to transform FBP measurements into PiB-like units.

resultsA mixture of two normal distributions fit both the FBP and PiB empirical data and provides a strong basis for derivation of a transfer function. Transforming Aβ-PET data with NoDiM results in FBP and PiB distributions that are closely aligned throughout their entire range, while a linear transformation does not. Additionally the NoDiM transform better matches true positive and false positive profiles across tracers. DISCUSSION: The NoDiM transformation provides a useful alternative to the linear mapping advocated in the Centiloid project, and provides improved correspondence between measurements from different tracers across the range of observed values. This improved alignment enables disparate measures to be merged on to continuous scale, and better enables the use of uniform thresholds across tracers.

Indexed as

AgingAniline CompoundsEthylene GlycolsModels, TheoreticalRadiopharmaceuticalsThiazolesAgedAged, 80 and overAlzheimer DiseaseBrainDatasets as TopicFemaleHumansImage Processing, Computer-AssistedMaleMiddle Aged2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsEthylene GlycolsflorbetapirRadiopharmaceuticalsThiazolesAlzheimer's diseaseAmyloidCentiloidHarmonizationPositron emission tomography

Identifiers

PMID30458305
PMCPMC6338495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.